Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 51, 2021 - Issue 5
219
Views
6
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel α2δ ligand, in healthy volunteers following oral administration

, , , , , , & show all
Pages 549-563 | Received 09 Nov 2020, Accepted 18 Jan 2021, Published online: 03 Feb 2021
 

Abstract

  1. The metabolism, excretion, and pharmacokinetics of mirogabalin were investigated following a single oral administration of [14C]mirogabalin at 30 mg/5.55 MBq to six healthy male subjects.

  2. The mean recovery values of radioactivity in urine and faeces were 96.85 and 1.21%, respectively. The main component of radioactivity in the plasma, urine, and faeces was mirogabalin. A204-4455 (lactam form), mirogabalin N-glucuronide, and glucuronide of oxidized A204-4455 were detected as minor components in the specimens. Renal clearance of mirogabalin was higher than the glomerular filtration rate of the human kidneys, indicating renal secretion is involved in the clearance.

  3. In vitro studies revealed that UDP-glucuronosyltransferase produced two metabolites: A204-4455, formed via mirogabalin acylglucuronide, and a ring-opened form of mirogabalin N-glucuronide.

  4. Mirogabalin was absorbed almost completely, and was eliminated via urine. A part of the orally administered dose of mirogabalin was metabolized through glucuronidation at the amine and carboxylic acid moiety, which represents the primary metabolic pathway.

Acknowledgements

The authors acknowledge Ling He (Daiichi Sankyo Pharma Development) for bioanalytical support. The authors expresses thanks to Hiroko Koda (Daiichi Sankyo Co., Ltd.) for structure elucidation of metabolites and Hideyuki Shiozawa to discuss ring size and its cyclization. The authors also acknowledge Takeo Kasagami (LSI Medience Corporation at the time of the study) for conducting quantitative metabolite profiling of the human specimen.

Disclosure statement

NY, MU, YU and MT are full-time employees of the Sponsor, Daiichi Sankyo. JM-H, HK, KB, VW, and VV were a full-time employee of Daiichi Sankyo at the time of the clinical study.

Additional information

Funding

This work was not supported by any funding agency.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.